Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
31
BNGO Quote, Financials, Valuation and Earnings
Last price:
$0.21
Seasonality move
:
246.06%
Day range:
$0.20 - $0.22
52-week range:
$0.19 - $2.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.30x
P/B ratio:
0.45x
Volume:
4M
Avg. volume:
3.2M
1-year change:
-89.04%
Market cap:
$22M
Revenue:
$36.1M
EPS (TTM):
-$4.48
Analysts' Opinion
-
Consensus RatingBionano Genomics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Bionano Genomics has an estimated upside of 362.96% from its current price of $0.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.22.
Fair Value
-
According to the consensus of 0 analysts, Bionano Genomics has 362.96% upside to fair value with a price target of -- per share.
BNGO vs. S&P 500
-
Over the past 5 trading days, Bionano Genomics has overperformed the S&P 500 by 1.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bionano Genomics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bionano Genomics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bionano Genomics reported revenues of $6.1M.
Earnings Growth
-
Bionano Genomics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bionano Genomics reported earnings per share of -$0.52.
Enterprise value:
14M
EV / Invested capital:
0.22x
Price / LTM sales:
0.30x
EV / EBIT:
--
EV / Revenue:
0.42x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$599K
Return On Assets:
-88.05%
Net Income Margin (TTM):
-407.34%
Return On Equity:
-158.95%
Return On Invested Capital:
-121.16%
Operating Margin:
-372.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $25.9M | $33.6M | $33.3M | $9.3M | $6.1M | |
| Gross Profit | $4.4M | $8.9M | -$599K | $2.7M | -$8.4M | |
| Operating Income | -$123M | -$150.5M | -$89.9M | -$35.9M | -$22.6M | |
| EBITDA | -$113.4M | -$212.4M | -$114.9M | -$108.8M | -$38.5M | |
| Diluted EPS | -$14.29 | -$18.15 | -$4.48 | -$3.22 | -$0.52 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.2M | $342M | $218.2M | $104.5M | $47M | |
| Total Assets | $41.4M | $359.7M | $323.7M | $181.9M | $87.4M | |
| Current Liabilities | $24.8M | $17.7M | $33.5M | $40.2M | $33M | |
| Total Liabilities | $26.7M | $18.1M | $42M | $62.9M | $38.5M | |
| Total Equity | $14.7M | $341.6M | $281.7M | $119M | $48.9M | |
| Total Debt | $16M | -- | -- | -- | $15M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$115.9M | -$129.9M | -$92.2M | -$26.3M | -$13.3M | |
| Cash From Investing | -$21.4M | $91.1M | $15.5M | $33.4M | -$5.4M | |
| Cash From Financing | $24.8M | $45.5M | $50.9M | $12.6M | $6M | |
| Free Cash Flow | -$118.8M | -$132.4M | -$93M | -$26.4M | -$13.3M | |
BNGO
Sector
Market Cap
$22M
$46.5M
Price % of 52-Week High
9.52%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
-129.47%
-0.6%
1-Year Price Total Return
-89.04%
-31.38%
Beta (5-Year)
2.279
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.21
200-day SMA
Sell
Level
$0.60
Bollinger Bands (100)
Sell
Level
0.25 - 0.45
Chaikin Money Flow
Sell
Level
-699.7M
20-day SMA
Sell
Level
$0.23
Relative Strength Index (RSI14)
Sell
Level
42.03
ADX Line
Buy
Level
19.74
Williams %R
Neutral
Level
-71.0526
50-day SMA
Sell
Level
$0.26
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
3.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4622)
Sell
CA Score
(Annual)
Level (-3.5941)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.6666)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Stock Forecast FAQ
In the current month, BNGO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BNGO average analyst price target in the past 3 months is --.
-
Where Will Bionano Genomics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bionano Genomics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Bionano Genomics?
Analysts are divided on their view about Bionano Genomics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bionano Genomics is a Sell and believe this share price will drop from its current level to --.
-
What Is Bionano Genomics's Price Target?
The price target for Bionano Genomics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BNGO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bionano Genomics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BNGO?
You can purchase shares of Bionano Genomics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bionano Genomics shares.
-
What Is The Bionano Genomics Share Price Today?
Bionano Genomics was last trading at $0.21 per share. This represents the most recent stock quote for Bionano Genomics. Yesterday, Bionano Genomics closed at $0.22 per share.
-
How To Buy Bionano Genomics Stock Online?
In order to purchase Bionano Genomics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 5.36% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 4.6% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.57% over the past day.
